Medulloblastoma Drug Market Report 2026

Medulloblastoma Drug Market Overview

• Medulloblastoma Drug market size has reached to $3.03 billion in 2025 • Expected to grow to $4.49 billion in 2030 at a compound annual growth rate (CAGR) of 8.2% • Growth Driver: Rising Incidence Of Brain Tumors Driving Market Growth Due To Advancements In Targeted Therapies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Medulloblastoma Drug Market?

Medulloblastoma drugs are medications used to treat medulloblastoma, a type of fast-growing brain tumor that originates in the cerebellum or posterior fossa, often in children. The treatment typically includes a combination of surgery, radiation therapy, and chemotherapy. These drugs target medulloblastoma and are primarily chemotherapy agents. The main types of medulloblastoma drugs are dianhydrogalactitol, investigational medicinal product 5471, ipilimumab, indoximod, and others. Dianhydrogalactitol is an alkylating agent used in cancer treatment, including medulloblastoma, which works by interfering with cancer cell DNA, preventing the cells from dividing and growing. It includes various products, such as chemotherapy drugs, targeted therapy drugs, and radiation therapy drugs, administered through intravenous, oral, and intrathecal routes. It is distributed through hospital pharmacies, online pharmacies, and retail pharmacies, catering to various end users including hospitals, home care, specialty centers, and others.

What Is The Medulloblastoma Drug Market Growth Forecast?

The medulloblastoma drug market size is expected to see strong growth in the next few years. It will grow to $4.49 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to growth in targeted brain cancer research, increasing survival rates, rising pediatric oncology investment, expansion of specialty centers, growth in rare disease funding. Major trends in the forecast period include rising use of combination chemotherapy regimens, growing focus on pediatric oncology care, increasing clinical trial activity for rare brain tumors, expansion of hospital-based cancer treatment, increased research into targeted brain cancer therapies.

Global Medulloblastoma Drug Market Segmentation

1) By Drug Candidate: Dianhydrogalactitol, Investigational Medicinal Product 5471, Ipilimumab, Indoximod, Other Types 2) By Product: Chemotherapy Drugs, Targeted Therapy Drugs, Radiation Therapy Drugs 3) By Route Of Administration: Intravenous, Oral, Intrathecal 4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy 5) By End-Users: Hospitals, Homecare, Speciality Centres, Other End-Users Subsegments: 1) By Dianhydrogalactitol: Dianhydrogalactitol Oral Formulations, Dianhydrogalactitol Intravenous Formulations 2) By Investigational Medicinal Product 5471: Oral Investigational Medicinal Product 5471, Intravenous Investigational Medicinal Product 5471 3) By Ipilimumab: Ipilimumab Monotherapy, Ipilimumab Combination Therapy 4) By Indoximod: Indoximod Oral Formulations, Indoximod Combination Therapy 5) By Other Types: Temozolomide, Lomustine, Cyclophosphamide, Targeted Therapy Drugs

What Are The Drivers Of The Medulloblastoma Drug Market?

The rising incidence of brain tumors is expected to propel the growth of the medulloblastoma drug market going forward. A brain tumor is an abnormal growth of cells in the brain or spinal canal that can be benign or malignant, potentially affecting brain function. The rising incidence of brain tumors is due to better detection, an aging population, environmental factors, increased awareness, and genetic predispositions. Medulloblastoma drugs, including chemotherapy, radiation, and targeted therapies, treat medulloblastoma by shrinking tumors, killing cancer cells, and preventing their spread. For instance, in January 2025, according to the American Cancer Society, a US-based non-profit organization focused on cancer research and patient support, an estimated 14,040 new cases of brain tumors and other nervous system cancers are expected in males and 10,780 in females in 2025, with total estimated deaths of 18,330. Therefore, the rising incidence of brain tumors is driving the growth of the medulloblastoma drug industry. The rising healthcare expenditure is expected to propel the growth of the medulloblastoma drug market going forward. Healthcare expenditure refers to the total spending on medical services, medications, preventive care, infrastructure, and administrative costs by governments, private entities, and individuals. The rising healthcare expenditure is due to factors such as an aging population, advancements in medical technology, the increasing prevalence of chronic diseases, and administrative costs. Healthcare expenditure drives the development of medulloblastoma drugs by funding research, clinical trials, and innovative treatments, enabling advancements in medical technology and specialized care for rare diseases. For instance, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based federal agency, in 2023, hospital expenditures rose by 10.4% to reach $1,519.7 billion, a faster increase compared to the 3.2% growth in 2022, and prescription drug spending grew by 11.4% to $449.7 billion in 2023, outpacing the 7.8% growth in 2022. Therefore, rising healthcare expenditure is driving the growth of the medulloblastoma drug industry. The increasing focus on personalized medicine is expected to propel the growth of the medulloblastoma drug market going forward. Personalized medicine refers to a medical approach that tailors treatment and healthcare strategies to the individual characteristics, genetics, and needs of each patient. The rise in personalized medicine is attributed to advancements in genomics, biotechnology, and data analytics, allowing treatments to be customized based on individual genetic profiles and other personal health data. The growing emphasis on personalized medicine supports the medulloblastoma drug by driving demand for targeted therapies, improving treatment efficacy, minimizing adverse effects, and enhancing survival rates in patients. For instance, in February 2024, according to Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. The newly approved personalized treatments for 2023 also include seven cancer drugs and three for other diseases and conditions. Therefore, the increasing focus on personalized medicine is driving the growth of the medulloblastoma drug industry.

Key Players In The Global Medulloblastoma Drug Market

Major companies operating in the medulloblastoma drug market are Pfizer Inc., Novartis AG, Roche Holding AG, Bristol-Myers Squibb Company, Merck & Co. Inc., AstraZeneca plc, Eli Lilly and Company, Amgen Inc., Sanofi S.A., Bayer AG, Eisai Co. Ltd., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Ipsen S.A., Daiichi Sankyo Co. Ltd., Jazz Pharmaceuticals plc, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Curtana Pharmaceuticals Inc., Biodexa Pharmaceuticals plc.

Regional Insights

North America was the largest region in the medulloblastoma drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Medulloblastoma Drug Market?

The medulloblastoma drug market consists of sales of chemotherapy drugs, targeted therapies, supportive care medications, steroids, and topoisomerase inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Medulloblastoma Drug Market Report 2026?

The medulloblastoma drug market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the medulloblastoma drug industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.